Radiomics-Based Visualization and Quantitative Validation of IDH1 Heterogeneity in Gliomas

Plain-language summary

This study aims to validate a model that predicts the distribution of IDH1 gene mutations from imaging data (radiomics) in patients with the brain tumor glioma. It enrolls patients aged 18 to 70 who have completed preoperative magnetic resonance imaging and been diagnosed with glioma. It is a study with no assigned phase and is currently active but not recruiting new participants (active, not recruiting).

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Active, not recruiting

Sponsor

Mingge LLC

Intervention

Validation of IDH1 mutations from the radiomics model

Start date

3/15/2019

Estimated completion

12/15/2026

Countries

China

Related genes

Locations

• Shanghai, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients aged 18-70 years, male or female;
* Patients with complete preoperative magnetic resonance imaging and were initially diagnosed with glioma based on the magnetic resonance imaging results;
* Patients who were proposed for craniectomy without contraindications to surgery and who had signed an informed consent form by themselves or their proxy;
* Patients with confirmed diagnosis of glioma by postoperative pathological diagnosis.

Exclusion Criteria:

* Patients to be admitted for a simple puncture biopsy;
* Patients with a combination of serious medical conditions and those who cannot tolerate surgery;
* Patients with a bleeding tendency or abnormal coagulation function, or those who have not discontinued long-term use of anticoagulants such as aspirin and clopidogrel;
* Pregnant and breastfeeding women;
* Patients participate in other clinical trials during the same period.